Please login to the form below

Not currently logged in
Email:
Password:

CDK4/6 inhibitor

This page shows the latest CDK4/6 inhibitor news and features for those working in and with pharma, biotech and healthcare.

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

Eli Lilly has picked up yet another FDA approval for CDK4/6 inhibitor Verzenio - its third in five months - as it tries to chase down Pfizer’s category-leading Ibrance. ... year and is predicted to become a $6bn product at peak by EvaluatePharma - as

Latest news

  • Novartis bags new breakthrough status for Kisqali in breast cancer Novartis bags new breakthrough status for Kisqali in breast cancer

    show that a CDK4/6 inhibitor can have a benefit in this setting. ... Meanwhile Novartis is trying to keep its new drug ahead of Eli Lilly’s CDK4/6 inhibitor Verzenio (abemaciclib), which was approved in the US - its first market - last September.

  • Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

    New phase III data for Novartis’CDK4/6 inhibitor Kisqali has shown that the drug is effective in tackling breast cancer in younger women. ... Novartis is currently a little ahead of Eli Lilly, whose CDK4/6 inhibitor Verzenio (abemaciclib) was approved

  • Lilly's abemaciclib data leaves potential uncertain Lilly's abemaciclib data leaves potential uncertain

    The MONARCH 3 trial was reported at the European Society of Medical Oncology (ESMO) conference in Madrid over the weekend, and showed that the CDK4/6 inhibitor prolonged progression-free survival ... This is a clinically relevant proportion of patients

  • Dismay as NICE turns down first-line use of AZ's Faslodex Dismay as NICE turns down first-line use of AZ's Faslodex

    trial, which showed that the drug was superior to the widely-used aromatase inhibitor anastrozole as a first-line treatment. ... While other drugs such as Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) and Novartis' rival Kisqali (ribociclib) "may yet

  • Novartis claims EU approval for breast cancer drug Kisqali Novartis claims EU approval for breast cancer drug Kisqali

    Novartis claims EU approval for breast cancer drug Kisqali. Firm's CDK4/6 inhibitor can now challenge Pfizer's Ibrance in Europe. ... Novartis can now challenge Pfizer's blockbuster breast cancer drug Ibrance in Europe after gaining approval for its

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics